Want to see PVLA full AI Analyst Report?
Top Page
Palvella Therapeutics
(NASDAQ:PVLA)
Select Model
Select Model
Rating:58Neutral
Price Target:
$146.00
▲(5.79% Upside)
Action:Reiterated
Date:08/04/26
PVLA’s score is anchored by weak current financial performance (no revenue, ongoing losses and cash burn), which is only partly offset by a strengthened balance sheet. Offsetting this, the earnings call signals strong clinical/regulatory momentum and clear guidance toward an NDA completion in H2 2026 with potential approval in H1 2027. Technically, the trend is moderately constructive, while valuation remains constrained by losses and the lack of a dividend.
Positive Factors
Compelling Phase III Efficacy
Robust, statistically and clinically meaningful Phase III SELVA results (95% improved) materially de-risk the core program, supporting regulatory approval, label strength, prescriber confidence and payer discussions. In rare diseases, a single pivotal trial of this magnitude sustains commercial and clinical differentiation over months.
Negative Factors
No Revenue and Large Ongoing Losses
The company remains pre-revenue with sizable recurring operating losses, meaning profitability is distant and commercial success must materialize to reverse returns. Persistent losses limit self-funding, pressure returns for investors, and make long-term success contingent on regulatory approval and successful commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Compelling Phase III Efficacy
Robust, statistically and clinically meaningful Phase III SELVA results (95% improved) materially de-risk the core program, supporting regulatory approval, label strength, prescriber confidence and payer discussions. In rare diseases, a single pivotal trial of this magnitude sustains commercial and clinical differentiation over months.
Read all positive factors
Palvella Therapeutics (PVLA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.99B
Dividend YieldN/A
Average Volume (3M)290.36K
Price to Earnings (P/E)―
Beta (1Y)0.26
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.83
Shares Outstanding14,342,844
10 Day Avg. Volume255,683
30 Day Avg. Volume290,357
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)42.09
Price to Sales (P/S)0.00
P/FCF Ratio-47.10
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$232.67Price Target Upside68.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-5.52
Revenue Forecast (FY)N/A
Palvella Therapeutics Business Overview & Revenue Model
Company Description
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to...
How the Company Makes Money
null...
Palvella Therapeutics Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Positive
The call highlights substantial clinical and regulatory progress—compelling Phase III SELVA results (95% improvement on primary endpoint), rolling review and first NDA module submission—supported by strong financial resources (~$251M cash) and accelerated commercial hiring (≈40 reps). Near-term risks include the need to complete the NDA, initial lack of Breakthrough for cVM (to be addressed with additional 24‑week data and qualitative evidence), increased 2026 cash spend to accelerate launch readiness, and multi-year timelines to expand indications beyond microcystic LMs. Overall, the positive clinical data, regulatory momentum, funding and clear commercial plan meaningfully outweigh the challenges and remaining execution risks.Positive Updates
Regulatory Milestones and NDA Progress
Completed an in-person pre-NDA meeting with FDA, received rolling review (available under Fast Track / Breakthrough), and submitted the first NDA module; remain on track to complete NDA submission in H2 2026 with potential FDA approval for QTORIN rapamycin in H1 2027.
Negative Updates
Breakthrough Therapy Not Initially Granted for cVM
FDA did not grant Breakthrough Therapy Designation for cutaneous venous malformations based on the initial 12-week package; company plans to resubmit with 24-week data and qualitative patient interviews to strengthen the case.
Read all updates
Q2-2026 Updates
Positive
Negative
Regulatory Milestones and NDA Progress
Completed an in-person pre-NDA meeting with FDA, received rolling review (available under Fast Track / Breakthrough), and submitted the first NDA module; remain on track to complete NDA submission in H2 2026 with potential FDA approval for QTORIN rapamycin in H1 2027.
Read all positive updates
Company Guidance
Palvella reiterated clear near-term regulatory and commercial guidance: rolling review granted and first NDA module submitted, with full NDA submission on track in H2 2026 and potential FDA approval in H1 2027; Phase III SELVA met its primary, key secondary and all four prespecified secondary endpoints (95% of patients improved on the primary at week 24; blinded mean mLM‑MCSS improved 3.4 points — 48% of maximum — and run‑in change was −0.1), the pediatric 6–11 cohort showed a mean mLM‑IGA improvement of 2.46 with 100% rated much/very much improved and all electing extension. Other program metrics: TOIVA (cVM) Phase II showed 73% responders and a Phase III start is planned in Q4 2026 (modeling a potential cVM approval in 2029); angiokeratoma LOTU Phase II (up to 15 patients) dosed in April with data expected H2 2027; DSAP Q2 Phase II planned (~15 patients) for Q4 2026. Epidemiology and commercial sizing: conservative U.S. diagnosed estimates >30,000 MLM (claims 45k–95k), >75,000 cVM (literature ~135k), >50,000 angiokeratomas, >50,000 DSAP — with potential addressable population >300,000 across indications. Commercial and financial guidance: ~$251M cash at 6/30/26 after a $230M Feb raise (original target $150M), 2026 cash spend ~$85–95M, launch field force ~40 reps (engaged >200 of 400 target clinics to date), pump covers up to 200 cm2 per actuation (30‑day supply), pricing guidance $100k–$200k/pt/yr, and regulatory pathways include Breakthrough/Fast Track/Orphan/Orphan Grant and a 505(b)(2) strategy.Palvella Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 25.90M | 31.42M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 23.12M | 29.05M |
| EBITDA | -50.00M | -35.90M | -13.12M | 18.69M | -30.50M | -43.37M |
| Net Income | -61.70M | -41.72M | -17.43M | 18.69M | -33.28M | -45.74M |
Balance Sheet | ||||||
| Total Assets | 253.51M | 59.56M | 88.23M | 7.55M | 16.52M | 153.56M |
| Cash, Cash Equivalents and Short-Term Investments | 250.58M | 57.98M | 83.60M | 7.35M | 16.05M | 117.76M |
| Total Debt | 535.00K | 633.00K | 0.00 | 0.00 | 0.00 | 14.89M |
| Total Liabilities | 36.58M | 31.58M | 25.63M | 11.43M | 39.70M | 102.81M |
| Stockholders Equity | 216.87M | 27.98M | 62.61M | -3.88M | -23.17M | 50.76M |
Cash Flow | ||||||
| Free Cash Flow | -47.38M | -25.01M | -10.84M | -13.70M | -14.84M | -8.61M |
| Operating Cash Flow | -47.38M | -25.01M | -10.84M | -13.70M | -14.84M | -7.66M |
| Investing Cash Flow | -117.91M | 0.00 | 0.00 | 0.00 | 0.00 | -949.00K |
| Financing Cash Flow | 430.94M | -660.00K | 87.09M | 5.00M | 9.57M | 59.13M |
Palvella Therapeutics Technical Analysis
Positive
138.01
Price Trends
133.25
Positive
127.39
Positive
111.43
Positive
Market Momentum
4.69
Negative
59.72
Neutral
84.58
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PVLA, the sentiment is Positive. The current price of 138.01 is below the 20-day moving average (MA) of 146.05, above the 50-day MA of 133.25, and above the 200-day MA of 111.43, indicating a bullish trend. The MACD of 4.69 indicates Negative momentum. The RSI at 59.72 is Neutral, neither overbought nor oversold. The STOCH value of 84.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PVLA.
Palvella Therapeutics Risk Analysis
Palvella Therapeutics disclosed 83 risk factors in its most recent earnings report. Palvella Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Palvella Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $873.82M | 7.45 | 43.85% | ― | 68.20% | ― | |
59 Neutral | $2.41B | -6.73 | -76.09% | ― | -58.40% | -31.99% | |
58 Neutral | $1.99B | -33.34 | -47.84% | ― | ― | ― | |
57 Neutral | $725.84M | -52.34 | -12.84% | ― | ― | 40.38% | |
52 Neutral | $1.90B | -14.62 | -42.66% | ― | ― | -33.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PVLA
Palvella Therapeutics
157.77
116.06
278.25%
TBPH
Theravance Biopharma
16.93
5.53
48.51%
MNPR
Monopar Therapeutics Inc
119.21
87.87
280.38%
NRIX
Nurix Therapeutics
25.53
15.88
164.56%
TYRA
Tyra Bioscience
26.51
16.41
162.48%
Palvella Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesFinancial DisclosuresProduct-Related Announcements
Palvella details QTORIN progress and Nasdaq uplisting milestones
Positive
Aug 4, 2026
On August 4, 2026, Palvella Therapeutics reported second-quarter 2026 results and detailed progress across its QTORIN pipeline, including submission of the first module of a rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations a...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Palvella Therapeutics Highlights Growth Plans and QTORIN Progress
Positive
Jul 15, 2026
On July 14, 2026, Palvella Therapeutics posted a new corporate presentation outlining its progress and growth plans, anchored by the QTORIN 3.9% rapamycin anhydrous gel program for microcystic lymphatic malformations. The company reported positive...
Business Operations and StrategyExecutive/Board Changes
Palvella Therapeutics Adds Industry Veteran to Board
Positive
Jun 30, 2026
On June 29, 2026, Palvella Therapeutics, Inc. expanded its Board of Directors from seven to eight members and appointed industry veteran Matthew Pauls as a Class I director, with his initial term running until the 2027 Annual Meeting of Stockholde...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Palvella Therapeutics Expands Equity Plan, Confirms Board Leadership
Positive
Jun 16, 2026
On June 10, 2026, at its Annual Meeting of Stockholders, Palvella Therapeutics’ investors approved an amendment to the 2024 Equity Incentive Plan, increasing the authorized shares available for issuance by 750,000, a move that expands the co...
Business Operations and StrategyProduct-Related Announcements
Palvella Reports Positive Phase 3 Data for QTORIN
Positive
May 20, 2026
On May 20, 2026, Palvella Therapeutics reported new positive Phase 3 SELVA and Phase 2 TOIVA clinical data for its topical QTORIN rapamycin gel at the International Society for the Study of Vascular Anomalies World Congress 2026 in Philadelphia, u...
Business Operations and StrategyProduct-Related Announcements
Palvella Unveils Promising Phase 2 Data for QTORIN
Positive
May 15, 2026
On May 15, 2026, Palvella Therapeutics reported new data from its Phase 2 TOIVA trial of topical QTORIN rapamycin in cutaneous venous malformations, presented at the 83rd Annual Meeting of the Society for Investigative Dermatology in Chicago. The ...
Delistings and Listing Changes
Palvella Therapeutics Upgrades Listing to Nasdaq Global Market
Positive
May 13, 2026
On May 11, 2026, Palvella Therapeutics, Inc. announced that it had received approval from the Nasdaq Listing Qualifications Department to transfer its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Market. The move, effec...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Palvella Highlights QTORIN Progress and Financing in Q1 Update
Positive
May 7, 2026
On May 7, 2026, Palvella Therapeutics reported first-quarter 2026 results and a broad corporate update, highlighting positive Phase 3 SELVA data for QTORIN rapamycin in microcystic lymphatic malformations, a granted FDA pre‑NDA meeting in th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.